Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128551 · ClinicalTrials.gov registry record · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 534
- Enrollment target
- 20
- Study locations
NCT06128551: Recruiting Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
NCT06128551 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 534 participants, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06128551, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 534 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Primary Outcome
Incidence and severity of treatment-emergent AEs and serious AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5
Conditions Studied
Interventions
- DRUG Elironrasib
- DRUG Daraxonrasib
Study Locations (20)
Texas
- Mary Crowley Cancer Research - Dallas
- MD Anderson - Houston
- NEXT Dallas - Irving
- NEXT Oncology San Antonio - San Antonio
- START Texas - San Antonio
California
- City of Hope - Duarte
- UC IRVINE Health - Orange
- UC Davis Comprehensive Cancer Center - Sacramento
- Stanford Cancer Institute - Stanford
New York
- Columbia University - New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center and Research Institute - Tampa
Michigan
- Henry Ford Cancer - Detroit
- START Midwest - Grand Rapids
Colorado
- University of Colorado Cancer Center - Aurora
Massachusetts
- Dana Farber Cancer Institute - Boston
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
What NCT06128551 shows while recruiting
NCT06128551 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Elironrasib is the first listed.
NCT06128551 names 20 study sites across 9 states, led by Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT06128551 about?
NCT06128551 is a clinical study titled "Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors". This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
What is the current status of trial NCT06128551?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 534 participants. The study started on 2023-11-14. Estimated completion is 2029-06.
What conditions does trial NCT06128551 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06128551?
The interventions under investigation include: Elironrasib (DRUG), Daraxonrasib (DRUG).
Who is sponsoring clinical trial NCT06128551?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128551 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06128551's enrollment target sits among peer trials
534 76th of 381 higher than 305 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI